AXSM FY 2022 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M

Gross Profit

$45M89.6% margin

Operating Income

-$180M-359.3% margin

Net Income

-$187M-374.0% margin

EPS (Diluted)

$-4.60

Cash Flow

Operating Cash Flow

-$117M

Free Cash Flow

-$117M

Stock-Based Comp.

$38M

Balance Sheet

Total Assets

$331M

Total Liabilities

$222M

Stockholders' Equity

$110M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$0	—
Gross Profit	$45M	$0	—
Operating Income	-$180M	-$125M	-44.2%
Net Income	-$187M	-$130M	-43.5%